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Abstract
Background: Among natural compounds, present in every day diet, flavonoids have shown beneficial effect in
prevention of cardiovascular diseases that can be attributed, at least partially to the described antiaggregatory
activity i.e. antiplatelet effects of flavonoids. Due to the ever increasing pharmacological interest in antiplatelet
agents a systematic experimental evaluation of large flavonoid series is needed.
Methods: A set of thirty flavonoid aglycones has been selected for the evaluation. All measurements of
aggregation were done under standardized and firmly controlled in vitro conditions. The whole blood samples,
multiple platelet functional analyzer and adenosine diphosphate (ADP) as a weak agonist of aggregation were
selected for this purpose.
Results: The results were expressed as minimal concentration of flavonoid that can significantly lower the platelet
aggregation compared to the corresponding untreated sample (minimal antiaggregatory concentration - MINaAC).
All analyzed flavonoids exhibited antiaggregatory activity MINaAC ranging from 0.119 μM to 122 μM, while the
most potent representatives were 3,6-dihydroxyflavone (0.119 μM) and syringetin (0.119 μM).
Conclusions: Measurable antiplatelet activity established at submicromolar flavonoid concentrations suggests that
even a dietary consumption of some flavonoids can make an impact on in vivo aggregation of platelets. These
findings also point out a therapeutical potential of some flavonoids.
Background
In the developed countries most of the older population
is affected by cardiovascular diseases. Platelets are
involved in haemostasis, thrombosis and inflammatory
processes, hence as a consequence of that physiological
role heart stroke and cerebrovascular insult can occur.
Most commonly used drug in prevention of mentioned
diseases is acetylsalicylic acid while clopidogrel repre-
sents another therapeutic option. Neither of these drugs
is free of side effects, thus the search for new and safer
drug from this group continues [1]. From the natural
compounds, present in every day diet, polyphenols,
mainly flavonoids (Figure 1), have shown beneficial
effect in prevention of cardiovascular diseases [2-7]. Fla-
vonoids naturally occur in a free form (aglycones) or
bound to a sugar moiety via hydroxyl groups
(glycosides).
Flavonoid antiplatelet activity can be attributed to the
increased production of prostacyclin by endothelian
cells. Prostacyclin decreases aggregation via synthesis of
cAMP - increased concentration of cAMP inhibits the
expression of platelet GPIIb/IIIa receptors [6]. In vitro
inhibition of cyclooxygenase, lipooxygenase, thyrosine
kinase, phosphodiesterase or phospholipase by flavo-
noids has also been documented and connected to their
antiplatelet activity [8-12]. Although different possible
mechanisms have been analyzed a unique mechanism of
antiaggregatory activity of flavonoids has not been
undoubtedly proven yet.
There are also doubts about antiaggregatory effective-
ness in vivo, due to high concentrations of flavonoids
that have been used in experiments in vitro (10 - 1000
μM) that can not be reached in vivo after oral intake
(0.6 μM) [13].
Most of the research on antiaggregatory effect of fla-
vonoids has been done using Born spectrophotometric
aggregometry. A major disadvantage of this method is
usage of platelets rich plasma (PRP) instead of whole
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a single concentration of flavonoids, and often the series
of tested flavonoids were small, thus limiting the overall
interpretation of the results [9,14-18]. Finally, influence
of biological variability has not been evaluated.
In this paper our objective was to analyse antiaggrega-
tory effect of a relatively large set consisting of 30 flavo-
noid aglycons. Instead of Born method impedance
aggregometry has been chosen as it enables usage of
whole blood. This method reduces problems related to
lack of standardization of PRP preparation and provides
insight to possible interactions of flavonoids with blood
components other than platelets. Biological triplicates of
all experiments have been made on blood samples taken
from three different blood donors. Along with the statis-
tical evaluation of difference between treated and
untreated samples this approach clearly minimizes
chance effects caused by large biological variability.
Methods
Materials
A set of thirty flavonoids has been tested. Structures and
t h en a m e so ft h es u p p l i e r sa r es t a t e di nt h eT a b l e1 ,
Table 2, Table 3, Table 4 and Table 5. Clopidogrel, an
ADP-receptor antagonist, was used as a positive control.
This substance was a kind gift of HALMED, Croatia. All
standards solutions were prepared by dissolving and
semi-dissolution (1/2
n) in dimethyl sulfoxide (DMSO,
Sigma-Aldrich, Switzerland) in the concentration range
of 500 mM to 30 nM depending of the flavonoid
Figure 1 Basic structure of flavonoids. Flavonoids are divided
into classes based on the structure of ring C. Basic structure
corresponds to flavan which are named flavanols (catechins) if
hydroxylated at position C3. Flavanones have keto group on
position C4. If the double bond C2 = C3 is present in structure
flavanols and flavanones are named flavones and flavanonols,
respectively. Isoflavonoids have B-ring at the position C3.
Table 1 Antiaggregatory activity of flavanons
Flavanons Structure MINaAC/μM p
Hesperetin
a
OH
H
OCH3 O H
O
O
O H
1.907 0.035
Homoeriodictyol
b H3CO
H
O
O O H
OH
OH 7.629 0.003
Isosakuranetin
b OCH3
O
O O H
OH
0.954 0.037
Pinocembrin
c
OH
O HO
O
15.259 0.010
Pinocembrin-7-methylether
c
OH
O
O
H3CO
0.954 0.025
Minimal antiaggregatory concentration of flavanons expressed in μM with statistical significance (p).
Flavonoids purchased from
aSigma-Aldrich, Switzerland,
bBioChemika, Switzerland,
cExtrasynthese, France.
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Flavones Structure MINaAC/μM p
6-hydroxyflavone
a
O
O
O H
0.954 0.030
7-hydroxyflavone
a
O
O O H
15.259 0.038
Acacetin
b
OCH3
O
O O H
OH
3.815 0.013
Apigenin
c
OH
OH
O
O
O H
 
3.815 0.037
Chrysin
c
O H
OH O
O
3.815 0.016
Chrysin dimethylether
d
O
O O
H3CO
C H3
1.907 0.025
Diosmetin
d
OCH3
O
O O H
OH
OH 7.629 0.021
Flavone
c
O
O
3.815 0.037
Luteolin
d
O
O O H
OH
OH
OH 7.629 0.029
Tangeretin
b
OCH3
O OCH3
H3CO
H3CO
OCH3
O
30.518 0.029
Tectochrysin
d
O
O OH
H3CO
0.954 0.013
Minimal antiaggregatory concentration of flavones expressed in μM with statistical significance (p).
Flavonoids purchased from
aChromaDex, USA,
bBioChemika, Switzerland,
cFluka, Germany,
dExtrasynthese, France.
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ments was 3%.
ADP was obtained from Dynabyte, Germany, and sal-
ine-CaCl2 (0.003 M CaCl2 in 0.9% NaCl) from Croatian
Institute of Transfusion Medicine, Croatia.
Freshly taken citrated blood (final citrate concentra-
tion 0.129 mol/L) was used for the measurement of
aggregation each time from three different healthy
volunteers per each flavonoid sample. This work was
approved by Ethical comities of Croatian Institute of
Table 3 Antiaggregatory activity of flavanonols
Flavanonols Structure MINaAC/μM p
3-hydroxyflavone
a
O
O
OH
1.907 0.019
3,6-dihydroxyflavone
a
O
O
OH O H
0.119 0.005
3,7-dihydroxyflavone
a
O
O O H
OH
1.907 0.001
Fisetin
b
O
O O H
OH
OH
OH 122.070 0.003
Galangin
c
O
O O H
OH
OH
122.070 0.008
Isorhamnetin
d OCH3
O
O O H
OH
OH
OH 7.629 0.029
Quercetin
e,* 15.259 0.047
Rhamnetin
d 0.954 0.041
Syringetin
d OCH3
OCH3
OH
O O H
OH O
OH
0.119 0.013
Minimal antiaggregatory concentration of flavanonols expressed in μM with statistical significance (p).
Flavonoids purchased from
aChromaDex, USA,
bExtrasynthese, France,
cSigma-Aldrich, Switzerland,
dBioChemika, Switzerland,
eFluka, Germany; *in the form of
quercetin dihydrate.
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Page 4 of 8Transfusion Medicine and Faculty of Pharmacy and Bio-
chemistry, University of Zagreb. A total number of 100
volunteers participated in this research. All volunteers
gave informed written consent.
Experimental procedure
Platelet aggregation was analyzed by Multiplate
® analy-
zer (Dynabyte, Germany). Generic procedure was used:
300 μL of blood was incubated for 6 minutes with 20
μL flavonoid solution and 300 μL of saline-CaCl2 pre-
heated at 37°C. For negative control (untreated sample)
20 μL of solvent - DMSO was used (final concentration
3%). Aggregation cascade was induced by adding 20 μL
of adenosine diphosphate reagent (ADPtest; final con-
centration of ADP 6.5 μM). Aggregation was measured
for 6 minutes and expressed as area under curve in arbi-
trary units (AU).
Data analysis
The results of antiaggregatory effect of flavonoids were
expressed as minimal antiaggregatory concentration
(MINaAC) that presents the lowest concentration of
flavonoid which can cause statistically significant
reduction of aggregation when compared to the
untreated sample. Procedure for determination of
MINaAC is illustrated on Figure 2. Statistical analysis
was performed using paired Student’st - t e s tw i t h i nR
v2.8.1 environment (Austria). Normal distribution of
aggregation on ten healthy volunteers was checked
using Shapiro-Wilk test (p = 0.501) justifying the use
of t-test.
Results and Discussion
All analyzed flavonoids exhibited antiaggregatory activity
with MINaAC ranging from 119 nM to 122 μM.
Table 4 Antiaggregatory activity of isoflavones
Isoflavones Structure MINaAC/μM p
Daidzein
a
O
O
OH
O H 15.259 0.048
Formononetin
a
OCH3
O
O
7.629 0.043
Genistein
a
O
O OH
O H
OH
30.518 0.013
Prunetin
a
H3CO O
O
OH
OH
7.629 0.033
Minimal antiaggregatory concentration of isoflavones expressed in μM with statistical significance (p).
Flavonoids purchased from
aExtrasynthese, France.
Table 5 Antiaggregatory activity of positive control and catechin
Substance Structure MINaAC/μM p
Epicatechin
a
O O H
OH
OH
OH
OH 1.907 0.030
Clopidogrel OCH3 O
Cl
N
S
0.019 0.029
Minimal antiaggregatory concentration of positive control and catechin expressed in μM with statistical significance (p).
Flavonoid purchased from
aSigma-Aldrich, Switzerland.
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pinocembrin, thus methylated derivates of flavanons
have greater antiaggregatory effect. Most potent flava-
nones are p-O-methylated derivates at B-ring (Table 1).
Monohydroxylated flavones are most potent if sub-
stituted at the position 6 of the A-ring (6-hydroxyfla-
vone, Table 2). However, most naturally occurring
flavonoids are hydroxylated at position 7 (7-
hydroxyflavone), thus having lower antiaggregatory
effect. Increase in number of hydroxyl groups does
not influence antiaggregatory effect (flavone, chrysin,
apigenin). Methylation increases antiaggregatory
effect, the same as it does in case of flavones (tecto-
chrysin > chrysin). If the flavone has more than four
substituents the activity decreases, even if methylated
(diosmetin, luteolin, tangeretin).
Figure 2 Design of the experiment. Aggregation of untreated sample (without adding the flavonoid, AUC0) and the sample of flavonoid (AUC)
are measured. If the difference of the aggregations is greater than 5% the measurement of additional two citrated bloods is performed.
Otherwise, double concentration of flavonoid is taken and the first step is repeated. If the flavonoid in the analysed concentration shows
statistically lower aggregation compared to the untreated sample (t-test) the analysed concentration is equal to minimal antiaggregatory
concentration (MINaAC). If not analysis is performed from the beginning with double the concentration of flavonoid. This presumes that the
analyzed concentration is not the first analysed (n > 1), else, the analysis is performed from beginning using the half of the concentration of
flavonoid. Example of prunetin is given. Aggregation of analysed concentration of prunetin: 3.8 μM is not greater than aggregation of the
untreated sample (58 U vs. 59 U). Thus additional measurement with double concentration (7.6 μM) of prunetin is performed. As the difference
of aggregation is greater than 5% (ΔAUC = 17%) measurements on two additional citrated blood samples were performed. The concentration
obtained is statistically different compared to the untreated sample (p = 0.033) thus minimal antiaggregatory concentration of prunetin is equal
7.6 μM. Note that red and blue lines in charts indicate two parallel measurements of the same sample. If the deviation between these two
measurements is greater than 10%, quality control flag appears and measurements should be repeated.
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gregatory effect than flavones (pinocembrin > chrysin),
opposite to methylated derivates (hesperetin > diosme-
tin, isosakuranetin > acacetin, pinocembrin-7-methy-
lether = tectochrysin).
Comparing monohydroxylated flavanonols to monohy-
droxylated flavones antiaggregatory effect is higher (3,6-
dihydroxyflavone > 6-hydroxyflavone, 3,7-dihydroxyfla-
vone > 7-hydroxyflavone). As it is the case with flavones,
increase in number of substituents (four and more)
decreases, while methylation increases antiaggregatory
effect (syringetin > rhamnetin > quercetin, Table 3).
Isoflavonoids are less potent antiaggregatory agents,
but the same as for flavonoids applies: increase in
hydroxylation decreases while methylation increases
antiaggregatory effect (Table 4). This is probably due to
greater volume and higher lipophilicity of the methyl
radical (V = 37.15, π = -0.09) compared to hydroxyl
group (V = 11.79, π = -0.74). Higher lipophilicity can
lead to significant interactions with the platelet’sm e m -
brane by increasing rigidity. The membrane is stabilized
and the appearance of the receptors - integrins e.g.
GPIIa/IIIb at the platelet surface is limited [19-21].
Epicatechin, present in wine, was the only catechin
analyzed (Table 5). It has greater antiaggregatory effect
compared to flavone and flavanonol parallels, namely
luteolin and quercetin.
Based on these observations, structure activity rela-
tionship between flavonoids (Figure 1) and antiaggrega-
tory activity reveals that:
- double bond at the position C2-C3 increases activ-
ity for hydroxylated derivates, but decreases activity
for methylated derivates at the ring A and B,
- hydroxyl group at the position C3 increases antiag-
gregatory activity,
- transfer of B ring from C2 to C3 decreases activity
(isoflavonoids),
- absence of carbonyl group at the position C4
increases activity,
- most potent flavonoids are substituted at the posi-
tion C6 of the ring A,
- O-methylation of the rings A and B increases
activity,
- if the rings A and B have 4 and more radicals
activity decreases.
The results of antiaggregatory effect of flavonoids were
compared to clopidogrel which acts as antagonist of
ADP and serves as positive control in the experiment
(Table 5). Although results for clopidogrel are compar-
able to results of the most potent flavonoids 3,6-dihy-
droxyflavone and syringetin, this should be interpreted
with caution. Clopidogrel is a pro-drug whose metabolic
activation to some extent can occur in vitro as main
enzyme responsible for activation CYP2C19 is present
in different tissues including the blood [22].
Dell’Agli et al. reported that inhibitory effect on plate-
let aggregation (induced by thrombin) of 10 μM concen-
tration of individual compound followed the order:
luteolin, quercetin and apigenin, the last being inactive
[9]. In our study MINaAC followed the other arrange-
ment: apigenin (3.815 μM), luteolin (7.629 μM), querce-
tin (15.259 μM), using ADP to induce aggregation.
Comparing the sets of flavonoids analyzed in our
research to the work of Navarro-Nuñez et al.w h e r e
antigreggatory effect was expressed as percentage of
inhibition of SQ 29548 binding to thromboxane A2
(TxA2) receptor, apigenin was the most potent antago-
nist of aggregation [23]. Thus, it achieves antiaggrega-
tory effect both through antagonism of thromboxane A2
receptors as well as ADP receptors. However, genistein
was next potent antagonist of TxA2 receptors, contrary
to our research where isoflavonoids showed lower
antagonism to ADP receptors compared to other classes
of flavonoids. Hesperetin has MINaAC of 1.907 μM, ten
to thirty times lower than reported by Jin et al., as
expected due to usage of strong agonists of aggregation
(collagen, arachidonic acid) [17].
The daily consumption of flavonoids is reported to be
m =2 3m gp e rd a y[ 2 4 ] .I fw et a k ei n t oa c c o u n tt h a t
absorption of flavonoid aglycone is f = 24% (as reported
for quercetin [25]) of the consumed dose it would mean
that concentration which can be achieved with normal
diet is:
c =
f ·
m
M
V
=3 . 7 µM
where M represents average molar mass of flavonoid
being 300 g/mol and V total blood volume of 5 L.
The most potent flavonoids cause minimal antiaggre-
gatory effect in even lower concentrations: 3,6-dihyroxy-
flavone, syringetin (MINaAC = 0.119 μM), 6-
hyroxyflavone, pinocembrin-7-methylether, tectochrysin,
rhamnetin and isosakuranetin (MINaAC = 0.954 μM).
These levels of flavonoids in serum have been experi-
mentally confirmed for the most commonly consumed
flavonoids: hesperetin and naringenin from orange juice,
and epi/catechins from coco and green tea - ranging
from 0.01 to 1.1 μM for individual flavonoid [26-29].
This is contrary to findings of Janssen et al.t h a tf l a v o -
noids are active in concentrations that can not be
achieved in vivo [13].
Conclusions
This work provides insight in the antiaggregatory activ-
ity of a relatively large set of flavonoid aglycons
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whole blood against ADP as an inductor. SAR of flavo-
noids shows that increase in the number of hydroxyl
groups at the rings A and B, decreases activity. On the
other hand, if O-methyl groups are introduced activity
increases. This indicates that the size/volume and lipo-
philicity of the radical is important factor, which should
be confirmed in further QSAR prediction studies.
The results obtained suggest that even a daily con-
sumption of flavonoids can effect aggregation of plate-
lets. As flavonoids are ubiquitous substances in plants,
this work can serve as source of information for further
assessment of food influence on antiaggregation/anticoa-
gulation treatment.
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